Guidance
Our Guidance explains the laws and regulations governing the development, manufacturing, marketing, and supply of therapeutic goods in Australia.
We recently introduced new features to improve your experience using Guidance on our website.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- (-) COVID-19 (11)
- Advertising (32)
- Breast implant hub (1)
- Clinical trials (5)
- Committees and advisory bodies (2)
- Compliance and enforcement (30)
- Cosmetics (4)
- Fees and payments (3)
- Import and export (9)
- Labelling and packaging (26)
- Legislation (9)
- Manufacturing (41)
- Medicinal cannabis hub (4)
- Metal-on-metal hip replacement implants hub (1)
- Safety monitoring and information (46)
- Scheduling (national classification system) (6)
- Shortages and supply disruptions (3)
- Sunscreens (2)
- Unique Device Identification (UDI) hub (2)
- Vaping hub (5)
- Weight loss products (1)
Search
48 result(s) found, displaying 26 to 48
-
GuidanceGuidance on whether medicines are evaluated as prescription medicines or complementary or over-the-counter (OTC) medicines.
-
GuidanceGuidance to assist sponsors and manufacturers in preparing their documentation for applications for COVID-19 rapid antigen tests.
-
GuidanceGuidance for sponsors of COVID-19 IVDs about their ongoing obligations
-
GuidanceGuidance for sponsors and manufacturers about pathways for exporting a ventilator from Australia.
-
GuidanceGuidance for sponsors on the eligibility criteria for reduced application and evaluation fees for major variation applications for prescription medicines.
-
GuidanceAustralian Regulatory Guidelines for Biologicals (ARGB). This guidance will help you understand how to classify your biological.
-
GuidanceThis guidance supports psychiatrists in understanding their regulatory requirements when prescribing MDMA and psilocybine from 1 July 2023.
-
GuidanceGuidance clarifying the interaction between our requirements and AHPRA advertising guidelines.
-
GuidanceGuidance on the rules governing COVID-19 rapid antigen tests (RATs) advertising.
-
GuidanceGuidance for new sponsors on how to supply, import, and export disinfectant products.
-
GuidanceGuidance relating to the supply of in vitro diagnostic medical devices for the detection of COVID-19/SARS-CoV-2 infections.
-
-
GuidanceGuidance explaining types of variations, for registered medicines and biologicals, that can be submitted as notifications due to being very low risk.
-
GuidanceGuidance on submitting an effective prescription medicines application.
-
GuidanceThis guidance is for sponsors and manufacturers supplying medicines in Australia that are serialised or have data matrix codes.
-
GuidanceTips for sponsors, distributors and retailers on creating prescription medicine labels that are compliant with Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines (TGO 91).
-
GuidanceGuidance to assist manufacturers of medical devices and their component parts with meeting their regulatory obligations.
-
GuidanceGuidance on obligations during provisional registration period, process for applying for extension of provisional registration and transition to full registration.
-
GuidanceGuidance on our approved terminology for medicines.
-
GuidanceRisk management plans for medicines and biologicals has been updated with new content, new Australia-Specific Annex and a new form.
-
GuidanceGuidance providing an overview of the Common Technical Document (CTD), modules 1-5. The CTD is a set of dossier specifications for the registration of medicines.
-
GuidanceGuidance on the two mechanisms to provide information about a drug substance sourced from a third-party manufacturer.
-
GuidanceGuidance on the regulatory requirements for therapeutic goods that contain, or are produced from, human blood or plasma.